RxDoctor Payments DataLook up a doctor →

James Lee, MD

Hematology & Oncology · Binghamton, NYNPI 1790773471

Payments from drug & device makers

$6,804,072in general payments, 2019–2025

Across 747 payments — averaging $9108.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3.7M
  • Genentech, Inc.$1.5M
  • Bristol Myers Squibb$438K
  • AstraZeneca$380K
  • Incyte Corporation$180K
  • Janssen Research & Development, LLC$140K
  • plus $464K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck69$3,695,124
Genentech, Inc.18$1,506,510
Bristol Myers Squibb16$437,956
AstraZeneca(2 entities)21$379,737
Incyte Corporation88$179,984
Janssen Research & Development, LLC8$140,193
Astrazeneca UK Limited1$125,632
Novartis46$124,656
Amgen14$111,136
GSK15$23,121
AbbVie31$20,085
E.r. Squibb & Sons, L.L.C.41$15,375
Bayer8$9,559
Jazz Pharmaceuticals Inc.12$9,398
Gilead(2 entities)21$7,976
Array Biopharma Inc8$6,257
Pfizer49$3,453
Regeneron Healthcare Solutions, Inc.4$2,345
Genentech USA, Inc.31$540
Johnson & Johnson(2 entities)25$513
Takeda Pharmaceuticals U.S.A., Inc.20$468
Astellas Pharma US Inc17$315
Daiichi Sankyo Inc.15$307
Puma Biotechnology, Inc.15$254
Lilly USA, LLC16$251
Sanofi7$243
Karyopharm Therapeutics Inc.11$203
Pharmacyclics LLC, An Abbvie Company9$191
Seagen Inc.10$163
Genmab U.S., Inc.8$136
EMD Serono, Inc.8$127
Acrotech Biopharma Inc.1$114
Myriad Genetic Laboratories, Inc.2$102
Taiho Oncology, Inc.6$101
Sun Pharmaceutical Industries Inc.5$96
Abiomed2$94
Clovis Oncology, Inc.2$84
Pharmaessentia USA Corporation4$81
Exelixis Inc.4$80
Apellis Pharmaceuticals, Inc.3$79
Ipsen Biopharmaceuticals, Inc4$74
Boehringer Ingelheim4$61
Eisai Inc.3$56
Blueprint Medicines Corporation2$55
Sumitomo Pharma America, Inc.3$54
Avyxa Pharma, LLC2$47
Rigel Pharmaceuticals, Inc.3$47
ADC Therapeutics America, Inc.3$45
Deciphera Pharmaceuticals Inc.3$44
Eagle Pharmaceuticals, Inc.1$40
Sobi, Inc3$39
G1 Therapeutics, Inc.2$37
Servier Pharmaceuticals LLC2$37
Pharmacosmos Therapeutics Inc.2$36
Lexicon Pharmaceuticals, Inc.2$33
Mirati Therapeutics, Inc.1$33
Morphosys, US Inc.2$29
Stemline Therapeutics Inc.1$28
Beigene USA, Inc.1$24
Aadi Bioscience, Inc.1$23

How this compares

$6,804,072 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024
$1,625,227
Medicare patients
624
Services billed
108,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Binghamton

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →